Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

The Lancet
November 13, 2017
Cited by 876Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis